Home

Anders D Hove

CIK 1365618 · last filed 2024-01-31

Anders D Hove is a corporate insider who has filed 43 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for ABIO, was dated Jan 31, 2024. Across all open-market trades the lifetime net is −$119.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions. 6 SEC filings were submitted jointly with BRYAN E ROBERTS.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.40M

Companies

9

Total Filings

43

Lifetime Open-Market Net

-$119.13M

Filer Profile

Reported Address
30 ROCKEFELLER PLAZA, SUITE 5508
NEW YORK, NY 10112
Related Filers
BRYAN E ROBERTS — 6 joint filings, latest 2014-07-30
ACORN CAPITAL ADVISORS GP, LLC — 2 joint filings, latest 2025-05-19
Bong Y Koh — 2 joint filings, latest 2015-06-17
NEUROCRINE BIOSCIENCES INC — 2 joint filings, latest 2010-01-05
VHCP Co-Investment Holdings II, LLC — 1 joint filings, latest 2015-06-17
Venrock Healthcare Capital Partners II, L.P. — 1 joint filings, latest 2015-06-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Oruka Therapeutics, Inc. (ABIO) Delisted Director 3,554 $28.80 $102.4K $0 5 2024-01-31
Anacor Pharmaceuticals, Inc. (ANAC) Delisted Director 0 $10.19 $0 -$187.53M 25 2016-06-24
EDGE Director 103,429 $52.18 $5.40M $4.95M 1 2015-10-08
Adverum Biotechnologies, Inc. (AAVL) Delisted 10%+ Owner 2,365,471 — — $61.20M 1 2014-08-07
CDE Director 0 $21.24 $0 $0 1 2012-08-06
WORLD HEART CORP (WHRT) Delisted Director 4,055,016 — — $2.00M 4 2011-06-27
Trubion Pharmaceuticals, Inc (TRBN) Delisted Director 0 — — $0 4 2010-10-28
Chelsea Therapeutics International, Ltd. (CHTP) Delisted 10%+ Owner 3,024,253 — — -$3.12M 1 2010-09-22
ALIMERA SCIENCES INC (ALIM) Delisted Director 242,867 $5.54 $1.35M $3.37M 1 2010-04-28

Recent Filings

43 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-01-31 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2022-12-19 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2021-01-13 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2018-03-05 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2017-02-21 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2016-06-24 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Disp (D) −33,886 -$3.36M EDGAR
2016-05-18 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Sell (S) −353,881 -$35.24M EDGAR
2016-04-15 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Conv (C) +257,647 $8.00M EDGAR
2016-04-11 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Sell (S) −229,301 -$16.30M EDGAR
2015-12-17 Anacor Pharmaceuticals, Inc. (ANAC) Delisted Sell (S) −900,000 -$100.12M EDGAR
Showing 1–10 of 43
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.